222 related articles for article (PubMed ID: 36700848)
1. Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma.
Dharanipragada P; Zhang X; Liu S; Lomeli SH; Hong A; Wang Y; Yang Z; Lo KZ; Vega-Crespo A; Ribas A; Moschos SJ; Moriceau G; Lo RS
Cancer Discov; 2023 Apr; 13(4):880-909. PubMed ID: 36700848
[TBL] [Abstract][Full Text] [Related]
2. Plasticity of Extrachromosomal and Intrachromosomal BRAF Amplifications in Overcoming Targeted Therapy Dosage Challenges.
Song K; Minami JK; Huang A; Dehkordi SR; Lomeli SH; Luebeck J; Goodman MH; Moriceau G; Krijgsman O; Dharanipragada P; Ridgley T; Crosson WP; Salazar J; Pazol E; Karin G; Jayaraman R; Balanis NG; Alhani S; Sheu K; Ten Hoeve J; Palermo A; Motika SE; Senaratne TN; Paraiso KH; Hergenrother PJ; Rao PN; Multani AS; Peeper DS; Bafna V; Lo RS; Graeber TG
Cancer Discov; 2022 Apr; 12(4):1046-1069. PubMed ID: 34930786
[TBL] [Abstract][Full Text] [Related]
3. Metastasis Suppressor NME1 Modulates Choice of Double-Strand Break Repair Pathways in Melanoma Cells by Enhancing Alternative NHEJ while Inhibiting NHEJ and HR.
Puts G; Jarrett S; Leonard M; Matsangos N; Snyder D; Wang Y; Vincent R; Portney B; Abbotts R; McLaughlin L; Zalzman M; Rassool F; Kaetzel D
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824412
[TBL] [Abstract][Full Text] [Related]
4. Disparate pathways for extrachromosomal DNA biogenesis and genomic DNA repair.
Rose JC; Wong IT; Daniel B; Jones MG; Yost KE; Hung KL; Curtis EJ; Mischel PS; Chang HY
bioRxiv; 2023 Oct; ():. PubMed ID: 37961138
[TBL] [Abstract][Full Text] [Related]
5. Multi-organ landscape of therapy-resistant melanoma.
Liu S; Dharanipragada P; Lomeli SH; Wang Y; Zhang X; Yang Z; Lim RJ; Dumitras C; Scumpia PO; Dubinett SM; Moriceau G; Johnson DB; Moschos SJ; Lo RS
Nat Med; 2023 May; 29(5):1123-1134. PubMed ID: 37106167
[TBL] [Abstract][Full Text] [Related]
6. Vemurafenib resistance reprograms melanoma cells towards glutamine dependence.
Hernandez-Davies JE; Tran TQ; Reid MA; Rosales KR; Lowman XH; Pan M; Moriceau G; Yang Y; Wu J; Lo RS; Kong M
J Transl Med; 2015 Jul; 13():210. PubMed ID: 26139106
[TBL] [Abstract][Full Text] [Related]
7. Breaking the vicious circle: Extrachromosomal circular DNA as an emerging player in tumour evolution.
Robert M; Crasta K
Semin Cell Dev Biol; 2022 Mar; 123():140-150. PubMed ID: 34857471
[TBL] [Abstract][Full Text] [Related]
8. Breakpoint profiling of 64 cancer genomes reveals numerous complex rearrangements spawned by homology-independent mechanisms.
Malhotra A; Lindberg M; Faust GG; Leibowitz ML; Clark RA; Layer RM; Quinlan AR; Hall IM
Genome Res; 2013 May; 23(5):762-76. PubMed ID: 23410887
[TBL] [Abstract][Full Text] [Related]
9. Targeted profiling of human extrachromosomal DNA by CRISPR-CATCH.
Hung KL; Luebeck J; Dehkordi SR; Colón CI; Li R; Wong IT; Coruh C; Dharanipragada P; Lomeli SH; Weiser NE; Moriceau G; Zhang X; Bailey C; Houlahan KE; Yang W; González RC; Swanton C; Curtis C; Jamal-Hanjani M; Henssen AG; Law JA; Greenleaf WJ; Lo RS; Mischel PS; Bafna V; Chang HY
Nat Genet; 2022 Nov; 54(11):1746-1754. PubMed ID: 36253572
[TBL] [Abstract][Full Text] [Related]
10. Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.
Song C; Piva M; Sun L; Hong A; Moriceau G; Kong X; Zhang H; Lomeli S; Qian J; Yu CC; Damoiseaux R; Kelley MC; Dahlman KB; Scumpia PO; Sosman JA; Johnson DB; Ribas A; Hugo W; Lo RS
Cancer Discov; 2017 Nov; 7(11):1248-1265. PubMed ID: 28864476
[TBL] [Abstract][Full Text] [Related]
11. The Potential of Targeting P53 and HSP90 Overcoming Acquired MAPKi-Resistant Melanoma.
Hsieh CC; Shen CH
Curr Treat Options Oncol; 2019 Feb; 20(3):22. PubMed ID: 30778775
[TBL] [Abstract][Full Text] [Related]
12. Chromothripsis drives the evolution of gene amplification in cancer.
Shoshani O; Brunner SF; Yaeger R; Ly P; Nechemia-Arbely Y; Kim DH; Fang R; Castillon GA; Yu M; Li JSZ; Sun Y; Ellisman MH; Ren B; Campbell PJ; Cleveland DW
Nature; 2021 Mar; 591(7848):137-141. PubMed ID: 33361815
[TBL] [Abstract][Full Text] [Related]
13. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors.
Zhang G; Frederick DT; Wu L; Wei Z; Krepler C; Srinivasan S; Chae YC; Xu X; Choi H; Dimwamwa E; Ope O; Shannan B; Basu D; Zhang D; Guha M; Xiao M; Randell S; Sproesser K; Xu W; Liu J; Karakousis GC; Schuchter LM; Gangadhar TC; Amaravadi RK; Gu M; Xu C; Ghosh A; Xu W; Tian T; Zhang J; Zha S; Liu Q; Brafford P; Weeraratna A; Davies MA; Wargo JA; Avadhani NG; Lu Y; Mills GB; Altieri DC; Flaherty KT; Herlyn M
J Clin Invest; 2016 May; 126(5):1834-56. PubMed ID: 27043285
[TBL] [Abstract][Full Text] [Related]
14. Functional redundancy between the XLF and DNA-PKcs DNA repair factors in V(D)J recombination and nonhomologous DNA end joining.
Oksenych V; Kumar V; Liu X; Guo C; Schwer B; Zha S; Alt FW
Proc Natl Acad Sci U S A; 2013 Feb; 110(6):2234-9. PubMed ID: 23345432
[TBL] [Abstract][Full Text] [Related]
15. Enhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance.
Yang Z; Wang Y; Liu S; Deng W; Lomeli SH; Moriceau G; Wohlschlegel J; Piva M; Lo RS
Cancer Discov; 2022 Aug; 12(8):1942-1959. PubMed ID: 35638972
[TBL] [Abstract][Full Text] [Related]
16. Distinct genomic features across cytolytic subgroups in skin melanoma.
Roufas C; Georgakopoulos-Soares I; Zaravinos A
Cancer Immunol Immunother; 2021 Nov; 70(11):3137-3154. PubMed ID: 33779796
[TBL] [Abstract][Full Text] [Related]
17. Starfish infers signatures of complex genomic rearrangements across human cancers.
Bao L; Zhong X; Yang Y; Yang L
Nat Cancer; 2022 Oct; 3(10):1247-1259. PubMed ID: 35835961
[TBL] [Abstract][Full Text] [Related]
18. Insight on ecDNA-mediated tumorigenesis and drug resistance.
Huang Q; Zhang S; Wang G; Han J
Heliyon; 2024 Mar; 10(6):e27733. PubMed ID: 38545177
[TBL] [Abstract][Full Text] [Related]
19. Acquired Cross-resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of
Choudhuri SP; Girard L; Lim JYS; Wise JF; Freitas B; Yang D; Wong E; Hamilton S; Chien VD; Gilbreath C; Zhong J; Phat S; Myers DT; Christensen CL; Stanzione M; Wong KK; Farago AF; Meador CB; Dyson NJ; Lawrence MS; Wu S; Drapkin BJ
bioRxiv; 2023 Jun; ():. PubMed ID: 37425738
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma.
Fattore L; Campani V; Ruggiero CF; Salvati V; Liguoro D; Scotti L; Botti G; Ascierto PA; Mancini R; De Rosa G; Ciliberto G
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32178301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
